Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a direct ...

文章核心观点 - C4 Therapeutics公司第三季度业绩超出市场预期 [1][2] - 公司过去4个季度中有2次超出共识EPS预期 [2] - 公司股价今年以来表现低于标普500指数 [3] - 公司未来业绩表现将取决于管理层在财报电话会议上的评论 [3] 公司业绩分析 - 第三季度营收为1536万美元,超出市场预期158.10% [2] - 这一数字较去年同期的1107万美元有所增长 [2] - 过去4个季度公司有2次超出共识营收预期 [2] - 第三季度每股亏损0.35美元,优于市场预期的0.40美元亏损 [1] - 这一数字较去年同期的0.55美元亏损有所改善 [1] - 公司一季度前预期第三季度每股亏损0.37美元,实际为0.26美元,超出预期29.73% [1] 行业展望 - 公司所属医疗-生物医药和遗传学行业目前在250多个扎克斯行业中排名前32% [8] - 扎克斯研究显示,排名前50%的行业相比排名后50%的行业,业绩表现通常会好2倍以上 [8] - 同行业公司Atyr Pharma预计第三季度每股亏损0.22美元,较去年同期下降10% [9] - Atyr Pharma第三季度营收预计为130万美元,较去年同期下降62.9% [9]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to _________________ ...

Exhibit 99.1 C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Cemsidomide Phase 1/2 Trial in Multiple Myeloma and non-Hodgkin's Lymphoma Continues to Progress: Data from Both Indications to be Presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA Initial Monotherapy CFT1946 Phase 1 Data Demonstrated Well-Tolerated Safety Profile and Early Evidence of Antitumor Activity; Phase 1/2 Trial Continues to Progress with Multiple Data Re ...

Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Discovery and Expansion of Leading Discovery and Clinical Portfolios Fisher Will Serve as Senior Scientific Advisor Until December 31, 2024 WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the appointment of Paige Mahaney, Ph.D. as the company's chief sc ...

CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities CFT1946 Achieves Dose Proportional Pharmacokinetic Exposure; Successfully Degrades BRAF V600 Mutant Protein Early Evidence of CFT1946 Monotherapy Anti-Tumor Activity in Patients Who Have Progressed on or After BRAF Inhibitor Therapies; Majority of Patients Demonstrated Tumor Reduction Across V600 Mutation Types CFT1946 Global Phase 1 Trial Continues to Enroll; Monotherapy and Combination Expansion Cohorts Advancing With Additional Dat ...

Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity Investor Webcast to be Held Friday, September 13, 2024 at 12:00 pm ET WATERTOWN, Mass., Sept. 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the abstract sharing clinical data from its ongoing Phase 1 clinical trial of CFT1946, a novel BiDAC™ degrader, ...

WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service. "We are excited to welcome Steve to the Board of Direc ...

WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in fireside chats at two September investor conferences. Fireside Chat Details: Event: Wells Fargo Healthcare Conference taking place in Boston, MA Date/Time: September 5, 2024 at 8:45 AM ET Event: 2024 Cantor Global Healthcare Conference taking place in New ...

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.73 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 29.73%. A quarter ago, it was expected that this company would post a loss of $0.41 per share when it actually produced a loss of $0.41, delivering no surprise. Over the last four quarters, the company has surpassed ...